Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations

European Journal of Radiology

Volumn 85, Issue 11, 2016, Pages 1934-1940

  Wang, Hua ^a   Schabath, Matthew B ^b   Liu, Ying ^a,b   Han, Ying ^a   Li, Qi ^a   Gillies, Robert J ^b   Ye, Zhaoxiang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

ALK; Computed tomography; EGFR; Histological subtype; Lung adenocarcinoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ADULT; AGE; ARTICLE; CANCER STAGING; CANCER SURGERY; CLINICAL EVALUATION; CLINICAL FEATURE; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR VOLUME; ADENOCARCINOMA; DIAGNOSTIC IMAGING; GENETICS; LUNG; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84986003667     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2016.08.023     Document Type: Article

References (26)

1. [1] Pao, W., Girard, N., New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:2 (2011), 175–180.
2. [2] Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A., Fukuoka, M., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361:10 (2009), 947–957.
3. [3] Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., Mano, H., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:7153 (2007), 561–566.
4. [4] Camidge, D.R., Kono, S.A., Flacco, A., Tan, A.C., Doebele, R.C., Zhou, Q., Crino, L., Franklin, W.A., Varella-Garcia, M., Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 16:22 (2010), 5581–5590.
5. [5] Wong, D.W., Leung, E.L., So, K.K., Tam, I.Y., Sihoe, A.D., Cheng, L.C., Ho, K.K., Au, J.S., Chung, L.P., Pik Wong, M., The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115:8 (2009), 1723–1733.
6. [6] Fukui, T., Yatabe, Y., Kobayashi, Y., Tomizawa, K., Ito, S., Hatooka, S., Matsuo, K., Mitsudomi, T., Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 77:2 (2012), 319–325.
7. [7] Shaw, A.T., Kim, D.W., Nakagawa, K., Seto, T., Crino, L., Ahn, M.J., De Pas, T., Besse, B., Solomon, B.J., Blackhall, F., Wu, Y.L., Thomas, M., O'Byrne, K.J., Moro-Sibilot, D., Camidge, D.R., Mok, T., Hirsh, V., Riely, G.J., Iyer, S., Tassell, V., Polli, A., Wilner, K.D., Janne, P.A., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368:25 (2013), 2385–2394.
8. [8] Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Varela, I., Phillimore, B., Begum, S., McDonald, N.Q., Butler, A., Jones, D., Raine, K., Latimer, C., Santos, C.R., Nohadani, M., Eklund, A.C., Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, Z., Downward, J., Futreal, P.A., Swanton, C., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366:10 (2012), 883–892.
9. [9] Cai, W., Lin, D., Wu, C., Li, X., Zhao, C., Zheng, L., Chuai, S., Fei, K., Zhou, C., Hirsch, F.R., Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung adenocarcinoma. J. Clin. Oncol. 33:32 (2015), 3701–3709.
10. [10] Choi, C.M., Kim, M.Y., Hwang, H.J., Lee, J.B., Kim, W.S., Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation. Radiology 275:1 (2015), 272–279.
11. [11] Yamamoto, S., Korn, R.L., Oklu, R., Migdal, C., Gotway, M.B., Weiss, G.J., Iafrate, A.J., Kim, D.W., Kuo, M.D., ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 272:2 (2014), 568–576.
12. [12] Park, J., Yamaura, H., Yatabe, Y., Hosoda, W., Kondo, C., Shimizu, J., Horio, Y., Yoshida, K., Tanaka, K., Oguri, T., Kobayashi, Y., Hida, T., Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy. Cancer Med. 3:1 (2014), 118–123.
13. [13] Halpenny, D.F., Riely, G.J., Hayes, S., Yu, H., Zheng, J., Moskowitz, C.S., Ginsberg, M.S., Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?. Lung Cancer 86:2 (2014), 190–194.
14. [14] Zhou, J.Y., Zheng, J., Yu, Z.F., Xiao, W.B., Zhao, J., Sun, K., Wang, B., Chen, X., Jiang, L.N., Ding, W., Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. Eur. Radiol. 25:5 (2015), 1257–1266.
15. [15] Rizzo, S., Petrella, F., Buscarino, V., De Maria, F., Raimondi, S., Barberis, M., Fumagalli, C., Spitaleri, G., Rampinelli, C., De Marinis, F., Spaggiari, L., Bellomi, M., CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur. Radiol. 26:1 (2016), 32–42.
16. [16] Kim, T.J., Lee, C.T., Jheon, S.H., Park, J.S., Chung, J.H., Radiologic characteristics of surgically resected non-Small cell lung cancer with ALK rearrangement or EGFR mutations. Ann. Thorac. Surg. 101:2 (2016), 473–480.
17. [17] Woo, T., Okudela, K., Yazawa, T., Wada, N., Ogawa, N., Ishiwa, N., Tajiri, M., Rino, Y., Kitamura, H., Masuda, M., Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer 65:3 (2009), 355–362.
18. [18] Travis, W.D., Brambilla, E., Nicholson, A.G., Yatabe, Y., Austin, J.H., Beasley, M.B., Chirieac, L.R., Dacic, S., Duhig, E., Flieder, D.B., Geisinger, K., Hirsch, F.R., Ishikawa, Y., Kerr, K.M., Noguchi, M., Pelosi, G., Powell, C.A., Tsao, M.S., Wistuba, I., The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J. Thorac. Oncol. 10:9 (2015), 1243–1260.
19. [19] Mirsadraee, S., Oswal, D., Alizadeh, Y., Caulo, A., van Beek, E. Jr., The 7th lung cancer TNM classification and staging system: review of the changes and implications. World J. Radiol. 4:4 (2012), 128–134.
20. [20] Shaw, A.T., Yeap, B.Y., Mino-Kenudson, M., Digumarthy, S.R., Costa, D.B., Heist, R.S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., Settleman, J., Kobayashi, S., Mark, E.J., Rodig, S.J., Chirieac, L.R., Kwak, E.L., Lynch, T.J., Iafrate, A.J., Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27:26 (2009), 4247–4253.
21. [21] Kim, H., Jang, S.J., Chung, D.H., Yoo, S.B., Sun, P., Jin, Y., Nam, K.H., Paik, J.H., Chung, J.H., A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype. PLoS One, 8(10), 2013, e76999.
22. [22] Kim, H., Chung, J.H., Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement. Transl Lung Cancer Res. 4:2 (2015), 149–155.
23. [23] Villa, C., Cagle, P.T., Johnson, M., Patel, J.D., Yeldandi, A.V., Raj, R., DeCamp, M.M., Raparia, K., Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. Arch. Pathol. Lab. Med. 138:10 (2014), 1353–1357.
24. [24] Kuo, M.D., Jamshidi, N., Behind the numbers: decoding molecular phenotypes with radiogenomics-guiding principles and technical considerations. Radiology 270:2 (2014), 320–325.
25. [25] Liu, Y., Kim, J., Qu, F., Liu, S., Wang, H., Balagurunathan, Y., Ye, Z., Gillies, R.J., CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. Radiology 280:1 (2016), 271–280.
26. [26] Wang, H., Schabath, M.B., Liu, Y., Berglund, A.E., Bloom, G.C., Kim, J., Stringfield, O., Eikman, E.A., Klippenstein, D.L., Heine, J.J., Eschrich, S.A., Ye, Z., Gillies, R.J., Semiquantitative computed tomography characteristics for lung adenocarcinoma and their association with lung cancer survival. Clin. Lung Cancer 16:6 (2015), e141–63.